CD19 and melanoma: Notably, 2xAARE-YB-CAR-Jun-T cells were more efficient at killing CD19+ melanoma cells than 2xAARE-YB-CAR-T cells were (Fig. 5D) and slightly decreased the expression of the exhaustion marker PD-1 without notable effects on LAG-3 and TIM-3 (Fig. 5E).